EU clears Avastin in platinum-resistant ovarian cancer; US next?
This article was originally published in Scrip
Executive Summary
The EU has approved the use of Roche's Avastin (bevacizumab) in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin chemotherapy as a treatment for women with recurrent ovarian cancer that is resistant to platinum-containing chemotherapy. There is currently no standard of care for this patient population.